Orthofix Medical Inc. Common Stock (DE) financials
$9.75−0.91%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 | FY19 Dec 31 | FY18 Dec 31 | FY17 Dec 31 | FY16 Dec 31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $822.3M | $799.5M | $746.6M | $460.7M | $464.5M | $406.6M | $460.0M | $453.0M | $433.8M | $409.8M |
| Gross profit | $566.0M | $545.9M | $486.3M | $337.2M | $349.6M | $304.7M | $359.3M | $356.4M | $340.8M | $321.9M |
| Gross margin | 68.8% | 68.3% | 65.1% | 73.2% | 75.3% | 74.9% | 78.1% | 78.7% | 78.6% | 78.6% |
| Operating income | -$81.4M | -$84.6M | -$139.1M | -$13.3M | -$8.3M | -$6.3M | -$18.8M | $30.1M | $40.8M | $21.1M |
| Net income | -$92.2M | -$126.0M | -$151.4M | -$19.7M | -$38.4M | $2.5M | -$28.5M | $13.8M | $6.2M | $3.1M |
| Net margin | −11.2% | −15.8% | −20.3% | −4.3% | −8.3% | 0.6% | −6.2% | 3.0% | 1.4% | 0.7% |
| Diluted EPS | $-2.33 | $-3.30 | $-4.12 | $-0.98 | $-1.95 | $0.13 | $-1.51 | $0.72 | $0.34 | $0.17 |
| EBITDA | $23.2M | -$222.0K | -$71.3M | $8.3M | $38.9M | $23.8M | $40.1M | $53.1M | $60.9M | $56.3M |
| Operating cash flow | $33.3M | $25.8M | -$45.8M | -$11.5M | $18.5M | $74.3M | $2.9M | $46.8M | $39.0M | $59.1M |
| Free cash flow | -$1.3M | -$9.1M | -$107.8M | -$34.7M | $690.0K | $58.8M | -$16.1M | $33.3M | $24.3M | $42.6M |
| Diluted shares | 39.6M | 38.1M | 36.7M | 20.1M | 19.7M | 19.4M | 18.9M | 18.9M | 18.5M | 18.5M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $82.0M | $83.2M | $33.1M | $50.7M | $87.8M | $96.3M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | — | — |
| Total debt | $175.3M | $175.6M | $113.6M | $19.9M | $22.5M | $22.8M |
| Total assets | $850.6M | $893.3M | $925.3M | $458.6M | $476.6M | $525.9M |
| Total liabilities | $400.6M | $390.2M | $326.6M | $121.8M | $139.7M | $169.0M |
| Shareholders' equity | $450.0M | $503.1M | $598.7M | $336.9M | $336.9M | $356.9M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology